NCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
Clinical Trials
10 trialsNCT01035658 2021-10-28
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
SCRI Development Innovations, LLC
Phase 1/2 Terminated
NCT02055690 2021-05-17
PAZOFOS
The Christie NHS Foundation Trust
Phase 1/2 Terminated
NCT01610206 2021-02-25
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
University of Virginia
Phase 2 Completed
NCT01392352 2020-02-13
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT01644825 2018-04-09
MITO-11
National Cancer Institute, Naples
Phase 2 Completed
NCT01608009 2017-03-10
PAZPET-1
Imperial College London
Phase 1 Completed
NCT01600573 2016-10-11
Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)
Charite University, Berlin, Germany
Phase 1/2 Unknown
NCT02348398 2016-08-16
Phase II Study of Pazopanib and Topotecan in Cervical Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01238770 2016-02-10
Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer
University Hospital Heidelberg
Phase 1/2 Completed